456 related articles for article (PubMed ID: 15448685)
1. 4-1BB-mediated immunotherapy of rheumatoid arthritis.
Seo SK; Choi JH; Kim YH; Kang WJ; Park HY; Suh JH; Choi BK; Vinay DS; Kwon BS
Nat Med; 2004 Oct; 10(10):1088-94. PubMed ID: 15448685
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms.
Choi BK; Asai T; Vinay DS; Kim YH; Kwon BS
Cytokine; 2006 Jun; 34(5-6):233-42. PubMed ID: 16899371
[TBL] [Abstract][Full Text] [Related]
3. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
4. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
[TBL] [Abstract][Full Text] [Related]
5. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
[TBL] [Abstract][Full Text] [Related]
7. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
[TBL] [Abstract][Full Text] [Related]
8. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
9. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.
Choi BK; Kim YH; Kang WJ; Lee SK; Kim KH; Shin SM; Yokoyama WM; Kim TY; Kwon BS
Cancer Res; 2007 Sep; 67(18):8891-9. PubMed ID: 17875731
[TBL] [Abstract][Full Text] [Related]
11. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
14. Suppressing the self in rheumatoid arthritis.
Mittler RS
Nat Med; 2004 Oct; 10(10):1047-9. PubMed ID: 15459704
[No Abstract] [Full Text] [Related]
15. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
16. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
17. Antigen-induced, tolerogenic CD11c+,CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis.
Min SY; Park KS; Cho ML; Kang JW; Cho YG; Hwang SY; Park MJ; Yoon CH; Min JK; Lee SH; Park SH; Kim HY
Arthritis Rheum; 2006 Mar; 54(3):887-98. PubMed ID: 16508971
[TBL] [Abstract][Full Text] [Related]
18. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L
Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117
[TBL] [Abstract][Full Text] [Related]
19. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses.
Tan JT; Ha J; Cho HR; Tucker-Burden C; Hendrix RC; Mittler RS; Pearson TC; Larsen CP
Transplantation; 2000 Jul; 70(1):175-83. PubMed ID: 10919597
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro.
Zhang L; Wang Q; Wang X; Ding P; Song J; Ma C; Sun W
Cell Mol Immunol; 2004 Feb; 1(1):71-6. PubMed ID: 16212924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]